Target Name: MIR4645
NCBI ID: G100616285
Review Report on MIR4645 Target / Biomarker Content of Review Report on MIR4645 Target / Biomarker
MIR4645
Other Name(s): MicroRNA 4645 | hsa-miR-4645-5p | mir-4645 | hsa-mir-4645 | hsa-miR-4645-3p | Mir-4645 | microRNA 4645

MIR4645: A Drug Target / Disease Biomarker

MIR4645, also known as interleukin-4645, is a protein that is expressed in various tissues throughout the body. It is a member of the interleukin family, which is a group of cytokines that play a crucial role in the immune system and other physiological processes. MIR4645 has been shown to have various functions, including regulating immune responses, cell signaling, and tissue repair. As a result, MIR4645 has potential as a drug target or biomarker in various diseases.

One of the key functions of MIR4645 is its role in regulating immune responses. MIR4645 has been shown to regulate the production of Th2 cells, which are a type of immune cell that play a key role in the development of autoimmune diseases such as rheumatoid arthritis and asthma. MIR4645 has been shown to inhibit the production of Th2 cells by suppressing the activation of STAT3, a protein that plays a key role in cell signaling.

Another function of MIR4645 is its role in cell signaling. MIR4645 has been shown to regulate the production of various signaling molecules, including STAT3, PD-L1, and NF-kappa-B. These molecules are involved in various cellular processes, including cell adhesion, migration, and inflammation. MIR4645 has been shown to inhibit the activity of these molecules and promote their degradation, which can lead to the inhibition of cell signaling.

MIR4645 has also been shown to have a role in tissue repair. MIR4645 has been shown to promote the production of regenerative cells, which are cells that are able to replace damaged or deleted cells in the body. This has potential applications in the treatment of various diseases, including cancer, where the loss of regenerative cells can lead to the development of invasive and deadly tumors.

In addition to its functions in regulating immune responses and promoting tissue repair, MIR4645 has also been shown to have potential as a drug target. MIR4645 has been shown to interact with various signaling molecules, including TGF-β1, which is a protein that plays a key role in the development of cancer. MIR4645 has been shown to inhibit the activity of TGF-β1 and promote its degradation, which can lead to the inhibition of its signaling. This has potential applications in the treatment of various diseases, including cancer.

MIR4645 has also been shown to interact with various signaling molecules involved in inflammation. MIR4645 has been shown to regulate the production of pro-inflammatory molecules, including IL-6 and IL-8. These molecules are involved in the development and maintenance of inflammation, and their production can contribute to the development of various diseases, including inflammatory bowel disease and asthma. MIR4645 has been shown to inhibit the activity of these molecules and promote their degradation, which can lead to the inhibition of their signaling. This has potential applications in the treatment of these diseases.

In conclusion, MIR4645 is a protein that has various functions in regulating immune responses, cell signaling, and tissue repair. Its potential as a drug target or biomarker makes it an attractive target for the development of new treatments for various diseases. Further research is needed to fully understand the functions of MIR4645 and its potential as a drug.

Protein Name: MicroRNA 4645

The "MIR4645 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4645 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4646 | MIR4647 | MIR4648 | MIR4649 | MIR4650-1 | MIR4650-2 | MIR4651 | MIR4652 | MIR4653 | MIR4655 | MIR4656 | MIR4657 | MIR4658 | MIR4659A | MIR4659B | MIR466 | MIR4660 | MIR4661 | MIR4662A | MIR4663 | MIR4664 | MIR4665 | MIR4666A | MIR4666B | MIR4667 | MIR4668 | MIR4669 | MIR4670 | MIR4671 | MIR4672 | MIR4673 | MIR4674 | MIR4675 | MIR4676 | MIR4677 | MIR4679-1 | MIR4679-2 | MIR4680 | MIR4681 | MIR4684 | MIR4685 | MIR4686 | MIR4687 | MIR4688 | MIR4689 | MIR4690 | MIR4691 | MIR4692 | MIR4693 | MIR4694 | MIR4695 | MIR4697 | MIR4697 host gene (non-protein coding) | MIR4698 | MIR4699 | MIR4700 | MIR4701 | MIR4703 | MIR4704 | MIR4706 | MIR4707 | MIR4708 | MIR4709 | MIR4711 | MIR4712 | MIR4713 | MIR4713HG | MIR4714 | MIR4715 | MIR4716 | MIR4717 | MIR4718 | MIR4720 | MIR4721 | MIR4722 | MIR4723 | MIR4724 | MIR4725 | MIR4726 | MIR4727 | MIR4728 | MIR4729 | MIR4730 | MIR4731 | MIR4732 | MIR4733 | MIR4734 | MIR4735 | MIR4736 | MIR4737 | MIR4738 | MIR4739 | MIR4740 | MIR4741 | MIR4742 | MIR4745 | MIR4746 | MIR4747 | MIR4749 | MIR4750